Maplelane Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Maplelane Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,020,000	Closed	-$85.8M	–	157
2015 Q2	$85.8M	Buy	+1,020,000	New	+$79.3M	2.96%	9

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Maplelane Capital's XBI Position: Q2 2016 in Review

Maplelane Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2016, closing a stake of 1 share.

Maplelane Capital first reported a position in XBI in Q2 2015 and held it in 2 quarters. The position peaked at $0 in Q1 2016. 201 funds tracked by Wall St. Rank hold XBI as of Q2 2016.

Maplelane Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2016 after selling out during the quarter.
Maplelane Capital sold 1 State Street SPDR S&P Biotech ETF share in Q2 2016.
Maplelane Capital first reported a position in State Street SPDR S&P Biotech ETF in Q2 2015 and held it in 2 quarters.
Maplelane Capital's State Street SPDR S&P Biotech ETF position peaked at $0 in Q1 2016.
201 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2016.

Based on Maplelane Capital's 13F filing for Q2 2016, filed 15 Aug 2016.